Nootropic Peptides: Semax and Selank, a Research Guide

Semax and Selank are two of the most-searched and most-discussed nootropic peptides in the research-peptide space, and they are not interchangeable. Semax is a synthetic ACTH(4-10) fragment studied mainly for neuroprotection and cognitive enhancement through BDNF and dopaminergic pathways. Selank is a synthetic tuftsin analogue studied mainly for anxiolytic and cognitive-modulation effects through GABAergic, serotonergic, and BDNF pathways. Both were developed at Russia's Institute of Molecular Genetics, both are live in The Peptide Lab's catalogue, and most of the published research on both remains Russian-language, with Western replication still limited but growing.

Semax is a synthetic analogue in the ACTH(4-10) family — derived from a short fragment of adrenocorticotropic hormone. Its full sequence is Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), which the primary literature describes precisely as Pro-Gly-Pro-ACTH(4-7): the four-residue ACTH(4-7) core (Met-Glu-His-Phe) extended with a C-terminal Pro-Gly-Pro tripeptide that increases stability and biological activity relative to the native fragment. Because it's built from a truncated ACTH sequence, Semax lacks the hormonal (adrenal-stimulating) activity of full-length ACTH — the interest in it isn't hormonal, it's neurological.

The mechanism research points at several overlapping pathways: upregulation of neurotrophic factors, particularly BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor); dopaminergic modulation; interaction with melanocortin receptors (MC3R, MC4R); and broad effects on neural gene expression, including anti-inflammatory activity in neural tissue (Dolotov et al., 2017, Frontiers in Pharmacology — Semax and BDNF/TrkB signaling). Semax has an unusually deep evidence base for a research peptide — over 400 published studies — and it holds regulatory approval as a nootropic/neuroprotective agent in Russia, which is part of why it shows up so often in Western researcher discussions despite most of the underlying literature being Russian-language.

Research applications cluster around neuroprotection models (including ischemia and stroke research), cognitive-enhancement studies, and neurotrophic factor expression analysis used to study neuroplasticity mechanisms more broadly.

Selank is a synthetic analogue of tuftsin, an endogenous immunomodulatory tetrapeptide. Selank itself is a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) — tuftsin's four-residue core extended with a C-terminal Pro-Gly-Pro tripeptide that confers resistance to enzymatic degradation and extends its biological half-life relative to native tuftsin. Like Semax, it was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences.

The mechanism research is broader than Semax's in one respect: alongside BDNF expression upregulation, Selank research covers GABAergic modulation, monoamine regulation (serotonin metabolism and dopamine turnover), enkephalin modulation, and retention of tuftsin's original immunomodulatory activity. That combination — anxiolytic-like effects without the sedation or dependence profile associated with classic GABAergic drugs, alongside a cognitive angle — is a relatively uncommon pairing in the research-peptide space, and it's the main reason Selank draws interest from researchers working at the intersection of cognition and emotional-state regulation rather than either domain alone.

Research applications cluster around anxiety-related behavior models, cognitive-function studies, stress-response research, and neuroimmune interaction studies (tied to the retained tuftsin activity).

The two get grouped together because they come out of the same research institute, share a BDNF-pathway mechanism, and are the two peptides researchers reach for first when the question is cognition rather than metabolism, recovery, or the GH axis. But the parent structures are unrelated — one derives from a stress hormone, the other from an immune peptide — and that difference in origin tracks a real difference in what each is actually studied for. A researcher whose question is neuroprotection or cognitive performance under stress is typically looking at Semax first. A researcher whose question involves anxiety-adjacent behavior models, or the cognition/emotional-regulation intersection specifically, is typically looking at Selank first. Some study designs use both, treating them as mechanistically distinct rather than substitutable — not a default stack the way Mod GRF 1-29 and Ipamorelin are on the GH axis.

Both peptides carry the same verification requirements as any other research compound in the catalogue, and the checks are identical for each: HPLC purity above 98%, mass spectrometry identity confirmation matching the expected molecular weight, sequence verification on the certificate, and cold-chain discipline in transit and storage. Because Semax and Selank are short, closely related-looking sequences from the same research lineage, a mislabeled vial is a real risk category worth checking for by name rather than assuming from the product listing.

Both compounds are supplied and sold strictly for laboratory research use. Neither is approved for human use in the United States, and nothing here is dosing guidance or a medical claim.

• Peptides for longevity research — the category map that places Semax and Selank inside the broader cognitive research cluster
• Peptide COA guide — how to read a Certificate of Analysis and the red flags that signal mislabeled material
• Best peptide vendors 2026 — the five-criteria framework for evaluating any supplier before ordering
• Products — current catalogue, including Semax and Selank

Research use only. The Peptide Lab supplies Semax and Selank for laboratory research use; nothing on this page is dosing guidance, a medical claim, or an endorsement of human use.